1John E. Ware. Cathy Donald Sherborbourne. The MOS 36. item short, form healthsurvey(SF - 36 ) : Ⅰ. Conceptual framework and item selection. Medical Care, 1992; 30(6)
2Colleen A. McHorney, John E. Ware. Anastasia E. Raczck. The MoS 36, item short, forrnhealth survey(SF - 361: Ⅱ. PsychometI' ic and clinical tests of validity in measuring physicaland mentallealth constructs. Medical ( : arc, 1 993 : 3 1 (3) :247.
3Cantare FB. Szejnfeld VL. Quality, of life patients with osteoporosis fractures: culturaladaptation, reliability and validity( ) rthe Ostcoporosis Assessment Questionnaire. Clin ExpRheumatol 1999; 17 f5):547-51.
4Deborah J. Cook. Gordon H. Guyatt. Jonathan D. Adachi, et al. Quality of life issues inwomen with vertebral fi' actures due to osteoporosis. Arthi 'iris and Rheumatism, 1 993 ; 36 (6) :750.
5Silverman - SL. Crannev- A. QualitY of life measurement in osteoporosiS. J - Rheumat01. 1997.1Ⅱil: 24 (6) : 1218 - 21.
6Chesnut CH. Tiludronate: dcvelopmenl as 111 osteoporosis therapy. Bone 1995 ; 1 7(5Suppl) : 5 1 7S. 9S.
7Josse RG. Prevention and management ol' ostcoporosis: consensus statements from theScientific Advisory Board ofthe Osteoporosis Society ofCanada. 3. Effects ofovarianhormone therapy on skeletaI and cxtraskelctaI tissues in women, Can Med ASSOC J1 996;1 55(7):929-34.
8JohneiI O. Advances in osteopol' osis: bettm' identification of risk factors can reducemorbidity and mortality. J Intcrn Med. 1 996 ; 239 (41 : 299-304.
9Clinical practice guidelines for t11e diao-nosis and nmnagemenl ofosteoporosis. ScientificAdvisory Boal d, Ostcop(n' osis Sociely of Canada. Can Med AssocJ 1996; 1 55(8): 1113- 33.
